Geode Capital Management
INTS icon

Geode Capital Management’s Intensity Therapeutics INTS Stock Holding History

Geode Capital Management’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$74.9K Sell
22,238
-549
-2% -$2.35K ﹤0.01% 4125
2026
Q2 		$93.4K Sell
22,787
-3,232
-12% -$15.2K ﹤0.01% 4114
2026
Q1 		$153K Buy
26,019
+7,609
+41% +$62.1K ﹤0.01% 4009
2025
Q4 		$189K Buy
18,410
+8,054
+78% +$81.7K ﹤0.01% 3925
2025
Q3 		$62.8K Buy
10,356
+7,443
+256% +$53.2K ﹤0.01% 4243
2025
Q2 		$22.4K Sell
2,913
-186
-6% -$3.82K ﹤0.01% 4349
2025
Q1 		$153K Buy
3,099
+525
+20% +$29.2K ﹤0.01% 3920
2024
Q4 		$114K Hold
2,574
– – ﹤0.01% 4066
2024
Q3 		$246K Buy
2,574
+669
+35% +$74.3K ﹤0.01% 3842
2024
Q2 		$233K Hold
1,905
– – ﹤0.01% 3860
2024
Q1 		$248K Buy
1,905
+91
+5% +$10.9K ﹤0.01% 3866
2023
Q4 		$389K Buy
1,814
+891
+97% +$93.8K ﹤0.01% 3710
2023
Q3 		$94.2K Buy
+923
New +$128K ﹤0.01% 4269

Other funds holding INTS

Kingsbury Capital Investment Advisors
Kingsbury Capital Investment Advisors Wilmette, Illinois $106M AUM
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
Mesirow Financial Investment Management
Mesirow Financial Investment Management Chicago, Illinois $6.47B AUM 15.41% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management's INTS Position: Q3 2026 in Review

Geode Capital Management reduced its Intensity Therapeutics (INTS) stake by 2.4% in Q3 2026, selling an estimated $2.35K and leaving 22,238 shares worth $74.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4125.

Geode Capital Management first reported a position in INTS in Q3 2023 and has held it in 13 quarters since. The position peaked at $389K in Q4 2023. 8 funds tracked by Wall St. Rank hold INTS as of Q3 2026.

  • Geode Capital Management held 22,238 shares of Intensity Therapeutics worth $74.9K as of Q3 2026.
  • Geode Capital Management sold 549 Intensity Therapeutics shares in Q3 2026, an estimated $2.35K.
  • Intensity Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #4125 holding.
  • Geode Capital Management first reported a position in Intensity Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • Geode Capital Management's Intensity Therapeutics position peaked at $389K in Q4 2023.
  • 8 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.